Blau Farmaceutica SA
BOVESPA:BLAU3
Blau Farmaceutica SA
Blau Farmacêutica SA engages in the manufacturing of pharmaceuticals. The company is headquartered in Cotia, Sao Paulo and currently employs 1,700 full-time employees. The company went IPO on 2021-04-19. The firm focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The firm operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.
Blau Farmacêutica SA engages in the manufacturing of pharmaceuticals. The company is headquartered in Cotia, Sao Paulo and currently employs 1,700 full-time employees. The company went IPO on 2021-04-19. The firm focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The firm operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.
Revenue: Blau reported third-quarter revenue of BRL 475 million, matching last year’s record quarter.
Gross Margin: Gross margin improved to 41%, or 42% excluding a BRL 8 million Hemarus plasma provision—the eighth consecutive quarterly increase.
Net Income: Reported net income rose sharply to BRL 106 million, up 52% year-on-year, boosted by accounting for Prothya-related interest and currency effects.
Bergamo Turnaround: Successful integration of Bergamo brought its margins in line with other Blau sites and was a key driver for margin improvement.
Capacity Expansion: Major production line expansions set to increase output by about 70% by 2026, with new lines coming online and further investments planned.
Launches and Pipeline: Product launches—especially in Aesthetics and monoclonal antibodies—were highlighted, with a 60% acceleration in pipeline revenue expected in the next cycle.
Hospital Segment: Hospital revenue growth was limited by production bottlenecks and a drop in public channel sales, though management sees this as temporary.
